Danone reports Q4 revenue EUR 6.68B vs. EUR 6.72B last year

In Q4 2025, sales stood at EUR 6,684m, up +4.7% LFL, with an increase of +2.5% from volume/mix and +2.1% from price. On a reported basis, sales decreased by -0.5%, negatively impacted by forex and others, mainly reflecting the depreciation of several currencies against the euro, notably the US dollar, the Argentine peso and the Chinese renminbi. In addition, scope and hyperinflation both contributed positively to reported sales. CEO Antoine de Saint-Affrique said, “In 2025, we again delivered broad-based, quality growth, reaffirming the strength and resilience of our health-focused portfolio. Like-for-like sales grew +4.5%, driven by positive volume/mix and supported by our multi-engine growth model. All categories and geographies contributed, with strong momentum in China, North Asia & Oceania, and sustained progress in Europe. We continued to perform, expand our recurring operating margin, improve ROIC and generate strong free cash flow, while transforming the company and reinvesting in capabilities, science, and innovation. As we advance Chapter 2 of Renew Danone (DANOY), we are reshaping our portfolio: scaling U.S. Medical Nutrition, strengthening our dairy strongholds, advancing microbiome science, and accelerating digitalization. Yet we remain clear-eyed: there is more to do and some areas still require further progress. Looking ahead to 2026, in a world that remains volatile, we remain disciplined and fully committed to our science-based and consumer and patient centric approach. We enter the year with confidence, aligned with the mid-term ambition we have set out.”